Área de Sócio

30.º aniversário

PRIMARY CARE SUMMIT ACADEMY 2022

PCS Academy

Hipercolesterolemia Familiar (HF)

 

Materiais informativos

Hipercolesterolemia Familiar (HF)

Desenvolvidos pelo “International FH Paediatric Register”.

Uma cortesia do Grupo de Investigação Cardiovascular do INSA para chegar as famílias com crianças com FH para que melhor compreendam a sua doença e vivam melhor com ela.

Foram desenvolvidos para idades diferentes com conteúdos adaptados:

segunda-feira, 01 agosto 2016 12:02

Nutracêuticos e compostos bioactivos do peixe para controlo das dislipidemias e redução do risco cardiovascular

Para além dos conhecidos PUFA e ácidos gordos Ω3, foram encontrados péptidos de hidrolisados de proteínas de peixe capazes de exercer efeitos antioxidantes, extensamente revistos em artigos recentes. Saiba mais sobre este assunto com o artigo que agora partilhamos, publicado na revista científica Marine Drugs.

Nutraceuticals and Bioactive Components from Fish for Dyslipidemia and Cardiovascular Risk Reduction.

Cardiovascular disease remains the most common health problem in developed countries, and residual risk after implementing all current therapies is still high. Permanent changes in lifestyle may be hard to achieve and people may not always be motivated enough to make the recommended modifications. Emerging research has explored the application of natural food-based strategies in disease management. In recent years, much focus has been placed on the beneficial effects of fish consumption. Many of the positive effects of fish consumption on dyslipidemia and heart diseases have been attributed to n-3 polyunsaturated fatty acids (n-3 PUFAs, i.e., EPA and DHA); however, fish is also an excellent source of protein and, recently, fish protein hydrolysates containing bioactive peptides have shown promising activities for the prevention/management of cardiovascular disease and associated health complications. The present review will focus on n-3 PUFAs and bioactive peptides effects on cardiovascular disease risk factors. Moreover, since considerable controversy exists regarding the association between n-3 PUFAs and major cardiovascular endpoints, we have also reviewed the main clinical trials supporting or not this association.

Chiesa G., Busnelli M., Manzini S., Parolini C.

Publicado em: Mar Drugs. 2016 Jun 8;14(6). pii: E113. doi: 10.3390/md14060113.

Aceda ao texto completo.